ARS Pharmaceuticals Enters Material Definitive Agreement
Ticker: SPRY · Form: 8-K · Filed: Oct 15, 2024 · CIK: 1671858
| Field | Detail |
|---|---|
| Company | Ars Pharmaceuticals, Inc. (SPRY) |
| Form Type | 8-K |
| Filed Date | Oct 15, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, definitive-agreement
Related Tickers: ABSI
TL;DR
ARS Pharma just signed a big deal, details TBD.
AI Summary
ARS Pharmaceuticals, Inc. entered into a Material Definitive Agreement on October 8, 2024. The filing does not disclose specific details of the agreement, such as the counterparty or financial terms, but indicates it is a significant event for the company.
Why It Matters
This filing signals a significant development for ARS Pharmaceuticals, potentially involving partnerships, acquisitions, or other crucial business arrangements that could impact its future operations and stock.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing regarding the nature and terms of the Material Definitive Agreement introduces uncertainty and potential risk.
Key Players & Entities
- ARS Pharmaceuticals, Inc. (company) — Registrant
- Silverback Therapeutics, Inc. (company) — Former company name
FAQ
What is the nature of the Material Definitive Agreement entered into by ARS Pharmaceuticals?
The filing does not specify the nature of the Material Definitive Agreement, only that one was entered into on October 8, 2024.
Who is the counterparty to this Material Definitive Agreement?
The filing does not disclose the name of the other party involved in the Material Definitive Agreement.
What are the key financial terms or obligations associated with this agreement?
The filing does not provide any details regarding the financial terms or obligations of the Material Definitive Agreement.
When was the Material Definitive Agreement officially entered into?
The Material Definitive Agreement was entered into on October 8, 2024.
Does this agreement represent a significant change in ARS Pharmaceuticals' business operations?
As a 'Material Definitive Agreement,' it is presumed to be significant, but the filing does not elaborate on the specific impact on business operations.
Filing Stats: 644 words · 3 min read · ~2 pages · Grade level 12.2 · Accepted 2024-10-15 07:02:01
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SPRY The Nasdaq
Filing Documents
- d902443d8k.htm (8-K) — 25KB
- 0001193125-24-237191.txt ( ) — 148KB
- spry-20241008.xsd (EX-101.SCH) — 3KB
- spry-20241008_lab.xml (EX-101.LAB) — 18KB
- spry-20241008_pre.xml (EX-101.PRE) — 11KB
- d902443d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARS PHARMACEUTICALS, INC. Date: October 15, 2024 By: /s/ Richard Lowenthal Richard Lowenthal, M.S., MBA President and Chief Executive Officer